Mental health app Lissun bags $3M for AI integration
Mental health platform Lissun in India has scored $2.5 million in a pre-Series A funding round led by RPSG Capital Ventures.
With its fresh funds, the startup plans to integrate AI into its suite of digital mental health solutions which target corporates, schools, and families of children with neurodevelopmental conditions. The new funds will also go to expanding their services and growing their team.
Proceeds from this new investing round bring its total investment to $5 million. Lissun last raised over $1 million in seed funding in September of the previous year.
Asan Medical Center first to prescribe locally-approved vision loss DTx
Asan Medical Center (AMC), one of South Korea’s biggest hospitals, has started prescribing a Korean-made digital therapeutic for visual impairment due to stroke.
The mobile-based application Vivid Brain provides training through virtual reality to enhance a user’s response to visual stimuli.
AMC officially prescribed the solution in September, five months after it was cleared by the Korean government – the third for a local DTx.
AMC professor Kang Dong-hwa, who developed Vivid Brain with Nunaps (a local company he founded), now plans to expand their DTx to hospitals locally and abroad.
Neurophet’s latest collab to predict Alzheimer’s risk
Korean medical imaging AI company Neurophet has announced a new partnership that will develop a new Alzheimer’s disease diagnosis platform.
In a statement, the company said it will collaborate with local biotechnology firm Aribio, which develops treatment for neurodegenerative diseases.
They intend to integrate Neurophet’s MRI-based image analysis software with Aribio’s blood-based Alzheimer’s diagnostic test to detect early people with Alzheimer’s-positive amyloid beta protein deposits in their brains.
Their solution, according to a press release, seeks to make Alzheimer’s testing more accessible, reducing repeat testing with the costly amyloid-PET imaging.
Neurophet and Aribio’s collaboration builds on their existing work in the global clinical trial of Aribio’s oral Alzheimer’s treatment AR1001, phase 3.
In July, Neurophet unveiled the Neurophet AQUA AD, its latest Alzheimer’s treatment prescription and monitoring software.
